145 results about "Nephritis" patented technology

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.

The invention provides an application of a reagent for detecting an effector CD4 + T cell in peripheral blood of a subject in preparation of a product for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The invention also provides an application of the effector CD4 + T cell in peripheral blood in preparation of a diagnostic model for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The marker is detected through flow cytometry, and the result shows that the Ejector CD4 + T cell is remarkably increased in a patient with membranous nephropathy, can effectively distinguish membranous nephropathy from healthy control (verification set AUC 0.8098), can assist in identifying membranous nephropathy, lupus nephritis (verification set AUC 0.8686) and ANCA-related vasculitis (verification set AUC 0.8968), and the level of the Ejector CD4 + T cell is related to whether membranous nephropathy is difficult to treat or not.

The application of phlorizin in the medicine for treating and / or preventing lupus nephritis, the molecular formula of phlorizin is C 21 H 24 O 10 , the application promotes the differentiation of regulatory T cells (Treg) by applying phlorizin to up-regulate the PI3K / Akt signal pathway, thereby reducing the symptoms of lupus nephritis, and provides an effective treatment method with less side effects. In the application, the traditional Chinese medicine monomer phlorizin can effectively promote the differentiation of Treg cells, and compared with compound traditional Chinese medicine, the use of single component has more advantages in drug efficacy control and efficacy evaluation. In addition, phlorizin is widely sourced, low in cost and non-toxic, and is very suitable for long-term treatment of lupus nephritis.

Disclosed herein is a method for treating immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) with the factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof (e.g., iptacopan hydrochloride).

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

Described herein are methods of treating immune complex mediated membrane proliferative glomerulonephritis (IC-MPGN) with a factor B inhibitor ipropam or a pharmaceutically acceptable salt thereof, e.g., ipropam hydrochloride.

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.

The application discloses a kind of biomarkers for evaluating systemic lupus erythematosus to lupus nephritis progression, prediction model and application, belong to lupus nephritis prediction technical field.The application provides a kind of for evaluating systemic lupus erythematosus to lupus nephritis progression prediction model, the prediction model is according to the ratio of biomarker CD8 / CD4 and the κ / λ ratio of naive B cell, carries out binary Logistic regression analysis, obtains LogitP value, by comparing the high and low of the LogitP value and critical value 0.66938, predicts systemic lupus erythematosus to lupus nephritis progression situation.The prediction model constructed in the application aims to identify the individuals in lupus patients who may develop into lupus nephritis.This innovative model not only provides important guidance in the diagnosis, prognosis prediction and efficacy evaluation of the disease, but also provides a new perspective for the clinical management of lupus nephritis.

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.

The invention relates to the field of medical care informatics, and discloses a lupus nephritis condition monitoring system based on TWEAK and CD163 dynamic change, which comprises a data adaptation gateway module, a data rationality arbitration engine, a time sequence regularization engine module, a high-order feature extraction engine module and a risk layering module, the time sequence regularization engine module switches an interpolation or smoothing algorithm based on a qualitative result of the data rationality arbitration engine and a time domain where a data point is located so as to generate a continuous time function. Through the information processing architecture, the technical problem that sparse asynchronous original medical data is prone to being affected by outlier pollution and end point distortion is solved, and the accuracy of data processing is improved. The system reconstructs discrete data snapshots into continuous mathematical objects, provides a stable and analyzable technical basis for subsequent extraction of interpretable high-order dynamic features, and improves the credibility of clinical decision support.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The present disclosure provides methods of treating or reducing the symptoms of glomerulonephritis in a subject.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to traditional Chinese medicine compound granules for treating lupus nephritis and a preparation method thereof. The formula of the traditional Chinese medicine compound granules comprises 25-35 parts of astragalus membranaceus, 8-12 parts of angelica sinensis, 8-12 parts of salvia miltiorrhiza, 25-35 parts of artemisia apiacea, 12-18 parts of caulis sinomenii, 25-35 parts of centella asiatica, 25-35 parts of raw malt and 25-35 parts of euonymus alatus. The medicinal materials are subjected to water extraction, extracting solutions are combined and concentrated into extract, maltodextrin, microcrystalline cellulose and soluble starch are selected as auxiliary materials to be dried and granulated, and the prepared traditional Chinese medicine compound granules are low in fine powder proportion, high in hardness and short in dissolution time. By adopting the dosage form of granules, not only are the characteristics of quick absorption and quick action of the decoction maintained, but also the defects of inconvenience in decoction, large dosage and easiness in mildewing during temporary use of the decoction are overcome, and the curative effect is remarkably improved.

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The present disclosure relates to methods and compositions for the treatment of a mammalian subject suffering from lupus the method comprising, administering to said subject a therapeutically effective amount of an orthogonal CAR-T cell directed against a B-cell antigen in combination with an engineered orthogonal IL2 ligand that selectively activates orthogonal CAR T cell expressing an engineered orthogonal CD122 receptor. In some embodiments, the lupus is systemic lupus erythramatosis (SLE). In some embodiments, the lupus is lupus nephritis. In some embodiments the subject suffering from lupus is also suffering from cytopenia. In some embodiments the methods are practiced in the absence of prior lymphodepletion of the subject.

The present invention belongs to the field of biomedical technology and specifically discloses the use of a substance that inhibits the activity and / or expression of a CAPG gene or protein in preparing a product for treating renal fibrosis caused by renal injury. The present invention first discovered through research that CAPG is expressed at a low level in normal renal tissue, but its expression level is elevated in renal tissue of patients with acute renal injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic nephropathy, indicating that CAPG expression may be involved in the occurrence and development of renal fibrosis caused by renal injury. Then, by constructing a CAPG knockout mouse model, it was found that knocking out CAPG can effectively reduce the progression of renal fibrosis. By culturing renal fibroblasts in vitro, it was found that silencing or knocking down CAPG can inhibit TGF-β-induced renal fibroblast activation. The research of the present invention is of great significance for the pathogenesis and treatment of renal injury or renal fibrosis.

The present invention relates to a nanoparticle comprising a nanomaterial and at least a first ligand and a second ligand tethered to the nanoparticle. The present invention also relates to a nanoparticle for use as a medicament or diagnostic agent. The present invention also relates to a nanoparticle for use in a method for preventing or treating a disease selected from the group consisting of diabetic nephropathy, glomerulonephritis, glomerular VEGF A dysregulation, endothelial VEGF A dysregulation, diabetic retinopathy, rheumatoid arthritis, age-related macular degeneration and cancer, such as breast cancer. Furthermore, the present invention relates to a method of preparing a nanoparticle.

Provided herein are methods for treating lupus nephritis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. Also provided herein are FcRn antagonists for use in treating lupus nephritis, and FcRn antagonists for use in the manufacture of medicaments for treating lupus nephritis.

Methods for treating primary glomerulonephritis, e.g., focal segmental glomerulosclerosis (FSGS), IgA nephropathy (IgAN) or mesangial proliferative glomerulonephritis (MsPGN) are provided.

This invention provides a traditional Chinese medicine composition for treating renal edema, pyelonephritis with ascites, and nephritis. It consists of over 20 herbs including Atractylodes lancea, Areca catechu, Saposhnikovia divaricata, and Alisma plantago-aquatica (specific formulation details can be found in the original text). It can be prepared as pills, granules, or decoctions for oral administration. Core efficacy: 1. Promotes diuresis and reduces swelling, eliminating renal ascites; 2. Clears heat and detoxifies, anti-inflammatory and antibacterial (synergistic effect on fungal infections and cervical erosion); 3. Regulates renal function and improves abnormal uric acid metabolism. Treatment plan: Mild cases: Use five basic formulas (①-⑤) composed of Codonopsis pilosula, Poria cocos, etc., taken three times daily; Severe cases: Use a potent diuretic formula containing Akebia trifoliata and Euphorbia pekinensis (one spoonful of pills twice daily); Treatment course is approximately one month, with a follow-up examination after three months. Advantages: Cure rate reaches 90%, low recurrence rate – pure traditional Chinese medicine preparation, no significant toxic side effects; also treats complications (fungal infection, cervical lesions). This treatment plan has been clinically verified through three generations and has significant efficacy in treating renal edema, ascites, and nephritis.

The utility model discloses an acute glomerulonephritis nursing auxiliary device which comprises a fixing frame, a sliding mechanism used for controlling the synchronous sliding direction is arranged in the fixing frame, the sliding mechanism comprises a rotating shaft rotationally connected to the interior of the fixing frame, a worm is fixedly connected to the rotating shaft, and the worm is fixedly connected to the fixing frame. And a fixing plate is fixedly connected to the interior of the fixing frame, a rotating roller is rotationally connected to the side, close to the worm, of the fixing plate, and a worm wheel is fixedly connected to the side, close to the worm, of the rotating roller. By arranging the sliding mechanism, the rotating handle can be rotated to drive the rotating shaft to rotate, the rotating shaft rotates to drive the worm on the rotating shaft to rotate synchronously, the worm rotates to drive the worm gear to rotate, the worm gear rotates to drive the threaded rod to rotate, and the threaded rod rotates to drive the nut on the threaded rod to slide. And finally, the nut can be synchronously pushed to slide through rotation of the rotating handle.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

The invention relates to the technical field of medical image processing, in particular to a lupus nephritis curative effect prediction system based on multi-staining kidney biopsy pathological images. The system comprises a feature extraction module used for extracting image features of staining biopsy images of patients, a similarity analysis module used for distinguishing reference patients from non-reference patients according to the image features, a data preparation module used for forming training samples, and a data processing module used for processing the training samples. And the prediction module is used for performing model training based on the training data and predicting the healing probability of the target patient. According to the scheme, the model can be helped to pay more attention to training data of biopsy samples which are similar to biopsy samples of a target patient and are effectively different from biopsy samples of other reference patients, the characteristic of high heterogeneity existing in lupus nephritis is matched, the information mining effect of the biopsy sample image of lupus nephritis is improved, and the accuracy of the biopsy sample image of lupus nephritis is improved. And a doctor is assisted to accurately complete evaluation of specific typing and severity of lupus nephritis of a patient.

The invention belongs to the technical field of biology, and relates to a construction method of a renal tubular interstitial nephritis-uveitis syndrome mouse model. Comprising the following steps: anesthetizing a mouse; carrying out subcutaneous injection on photoreceptor intercellular vitamin A binding proteins and a complete Freund's adjuvant on the front neck, the thighs on the two sides and the back of the anesthetized mouse, and carrying out active immunization; and performing intraperitoneal injection on the actively immunized mouse by adopting pertussis toxin, and performing final immunization. According to the invention, the renal tubular interstitial nephritis-uveitis syndrome mouse model is successfully constructed, so that a foundation is laid for subsequent pathological mechanism research of the disease, and a support can be provided for further development of medicine research for treating the disease.

The invention discloses application of MMP-8 as a lupus nephritis marker and a medicine for inhibiting lupus nephritis, and belongs to the technical field of biomarkers. The expression characteristic, diagnostic value and pathogenic mechanism of MMP-8 in lupus nephritis are found for the first time, a new potential biomarker is provided for clinical diagnosis of LN, and the key effect of pDCs and MMP-8 in kidney injury of LN patients is disclosed; and a new angle is provided for preventing or inhibiting the lupus nephritis, so that the MMP-8 inhibitor can be screened or developed to treat the lupus nephritis.

To provide a new method for treating lupus nephritis (LN), which improves renal response, reduces recurrence, prevents eventual end-stage renal disease (ESRD), and reduces the need for glucocorticoids.SOLUTION: WHAT IS CLAIMED IS: 1. A method of reducing lupus nephritis (LN) disease activity in a subject in need thereof, comprising administering to the subject a type I IFN receptor (IFNAR1) inhibiting agent. Preferably, the IFNAR1 inhibitors are human monoclonal antibodies specific for IFNAR1, such as anifrolumab.SELECTED DRAWING: None

The invention belongs to the field of medicinal chemistry and biological medicine, and discloses 3 '-O-sodium sulfonate quercetin as well as a preparation method and medical application thereof, the chemical name of the compound is 3, 5, 7, 4'-tetrahydroxyflavone-3 '-O-sodium sulfonate, the molecular formula is CHOSNa, and the compound is a novel derivative obtained by taking quercetin as a mother nucleus and carrying out specific sulfonation on 3'-hydroxyl and forming sodium salt. Quercetin and a sulfur trioxide-pyridine compound are used as main raw materials, sulfonation, salification, decoloration and freeze drying are performed, the process is mild, the specificity is high, the product yield is larger than or equal to 80%, the purity is larger than or equal to 99%, and the method is suitable for industrial production. The water solubility of the compound is improved by more than 4000 times compared with that of natural quercetin, the bioavailability is remarkably enhanced, and the compound has excellent anti-inflammatory activity, can specifically inhibit release of inflammatory factors such as TNF-alpha and IL-6, can be prepared into various dosage forms in compatibility with pharmaceutical auxiliary materials, is used for treating inflammation-related diseases such as inflammatory bowel diseases, rheumatoid arthritis and glomerulonephritis, and has wide application prospects. The invention provides an efficient and low-toxicity novel candidate drug for inflammation treatment, and has a good clinical application prospect.

Disclosed is a method for treating autoimmune diseases, wherein a therapeutically effective amount of a proteasome inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof is administered to a patient with autoimmune diseases. This method has a certain therapeutic effect on patients with autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis (LN), and autoimmune hepatitis. The proteasome inhibitor or the pharmaceutically acceptable salt or pharmaceutical composition thereof has low toxicity, thereby showing excellent clinical application prospects.